全球即时护理 (POC) 分子诊断市场

Point of Care (POC) Molecular Diagnostics

出版日期: 2024年08月05日 | 出版商:

Global Industry Analysts, Inc. | 英文 597 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球即时 (POC) 分子诊断市场将达到 88 亿美元

预计到 2023 年，全球床边 (POC) 分子诊断市场规模将达到 37 亿美元，预计 2023 年至 2030 年复合年增长率为 13.1%，到 2030 年将达到 88 亿美元。基于 PCR 的 POC 分子诊断是本报告分析的细分市场之一，预计复合年增长率为 14.0%，到分析期结束时将达到 57 亿美元。在分析期间，基于基因定序序的 POC 分子诊断领域的复合年增长率预计为 10.5%。

美国市场预计15亿美元，中国预计复合年增长率15.9%

到 2023 年，美国床边 (POC) 分子诊断市场预计将达到 15 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达10亿美元，2023-2030年分析期间复合年增长率为15.9%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 10.7% 和 12.2%。在欧洲，德国的复合年增长率预计约为 12.3%。

全球护理点 (POC) 分子诊断市场 - 主要趋势和驱动因素总结

护理点 (POC) 分子诊断在更接近患者护理点而不是在中心实验室进行分子诊断测试。该技术可以透过核酸分析快速检测疾病，在几分钟到几小时而不是几天内即可获得结果。其目的是向医疗保健提供者提供及时的信息，以便立即做出临床决策和开始治疗。 POC 分子诊断设备通常是可携式或手持式的，旨在只需最少的培训即可轻鬆使用，并且比传统的实验室测试具有更少的操作步骤。这种快速、方便的检测形式在感染疾病、遗传性疾病和癌症以及其他医学应用的管理中特别有用。

POC 分子诊断的效用在世界各地的医疗保健环境中变得越来越明显，特别是在急诊室、加护病房和传统检测设施有限的偏远地区。在感染疾病管理中，例如流感、COVID-19 和其他病毒感染疾病的及时诊断，POC 检测可以透过快速隔离决策来显着减少感染的传播。此外，在肿瘤学等环境中，POC 分子诊断可以促进肿瘤标记和突变的即时评估，从而在治疗时直接製定个人化治疗策略。这项技术可以适应药房和社区诊所等非医院环境，进一步扩大其覆盖范围和影响，使更多人能够获得诊断服务。

POC 分子诊断市场的成长受到多种因素的推动。提高 POC 设备的准确性、速度和易用性的技术进步为市场扩张做出了重大贡献。此外，多路復用功能的开发正在取得进展，该功能允许在同一设备上同时执行多项测试，从而大大提高了 POC 诊断的效用和吸引力。此外，全球感染疾病负担日益增加，以及疫情管理中对快速诊断方法的需求不断增加，凸显了 POC 检测的重要作用。经济因素，例如住院时间的缩短以及由于减少对集中检测设施的依赖而降低的成本，也推动了 POC 诊断在各种医疗机构中的采用。消费行为，特别是对即时医疗服务的期望不断提高以及对个人化医疗意识的提高，进一步推动了对这些创新诊断解决方案的需求。

受访企业范例（共64家）

Bayer AG
Danaher Corporation
DiaSorin SpA
Biocartis NV
Maxim Biomedical, Inc.
AccuBioTech Co., Ltd.
Abacus Diagnostica Oy
genedrive plc
Molbio Diagnostics Pvt. Ltd.
Mesa Biotech, Inc.
Binx Health
Credo Diagnostics Biomedical Pte. Ltd
Genestat Molecular Diagnostics, LLC
Alveo Technologies
ADOR Diagnostics

The global market for Point of Care (POC) Molecular Diagnostics estimated at US$3.7 Billion in the year 2023, is expected to reach US$8.8 Billion by 2030, growing at a CAGR of 13.1% over the analysis period 2023-2030. PCR-based POC Molecular Diagnostics, one of the segments analyzed in the report, is expected to record a 14.0% CAGR and reach US$5.7 Billion by the end of the analysis period. Growth in the Genetic Sequencing-based POC Molecular Diagnostics segment is estimated at 10.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.5 Billion While China is Forecast to Grow at 15.9% CAGR

The Point of Care (POC) Molecular Diagnostics market in the U.S. is estimated at US$1.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.0 Billion by the year 2030 trailing a CAGR of 15.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 10.7% and 12.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.

Global Point of Care (POC) Molecular Diagnostics Market - Key Trends and Drivers Summarized

Point of Care (POC) molecular diagnostics involves the performance of molecular diagnostic tests near the site of patient care rather than in a central laboratory. This technology enables the rapid detection of diseases through nucleic acid analysis, providing results within minutes or hours rather than days. The aim is to deliver timely information to healthcare providers, enabling immediate clinical decision-making and treatment initiation. POC molecular diagnostic devices are typically portable or handheld, designed to be easy to use with minimal training, and require fewer operational steps compared to traditional lab-based tests. This rapid and convenient form of testing is particularly valuable for managing infectious diseases, genetic conditions, and cancer, among other medical applications.

The utility of POC molecular diagnostics has become increasingly evident in healthcare settings around the world, particularly in emergency rooms, intensive care units, and remote areas where access to conventional lab facilities may be limited. In infectious disease management, such as the timely diagnosis of influenza, COVID-19, and other viral infections, POC testing can drastically reduce the spread of infections by enabling quick isolation decisions. Additionally, in settings like oncology, POC molecular diagnostics facilitate the real-time assessment of tumor markers and mutations, which can guide personalized treatment strategies directly at the point of care. The technology's adaptability to non-hospital environments, such as pharmacies and community clinics, further extends its reach and impact, making diagnostic services accessible to a broader population.

The growth in the POC molecular diagnostics market is driven by several factors. Technological advancements that enhance the accuracy, speed, and user-friendliness of POC devices are major contributors to market expansion. The ongoing development of multiplexing capabilities, where multiple tests are conducted at the same time on the same device, also significantly boosts the utility and attractiveness of POC diagnostics. Furthermore, the increasing global burden of infectious diseases and the rising demand for rapid diagnostic methods in pandemic management highlight the critical role of POC testing. Economic factors, including cost savings associated with reduced hospital stays and less reliance on centralized laboratory facilities, encourage the adoption of POC diagnostics across various healthcare settings. Consumer behavior, particularly the growing expectation for immediate healthcare delivery and the rising awareness of personalized medicine, further propels the demand for these innovative diagnostic solutions.

Select Competitors (Total 64 Featured) -

Bayer AG
Danaher Corporation
DiaSorin SpA
Biocartis NV
Maxim Biomedical, Inc.
AccuBioTech Co., Ltd.
Abacus Diagnostica Oy
genedrive plc
Molbio Diagnostics Pvt. Ltd.
Mesa Biotech, Inc.
Binx Health
Credo Diagnostics Biomedical Pte. Ltd
Genestat Molecular Diagnostics, LLC
Alveo Technologies
ADOR Diagnostics

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
- Point of Care (POC) Molecular Diagnostics - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Molecular Diagnostics: Leveraging Molecular Technologies to Monitor Human Diseases
- Types of Molecular Diagnostics Tests
- An Introduction to Point of Care (POC) Molecular Diagnostics
- Molecular Testing Mechanisms
- Molecular Vs Non-Molecular POCT
- Global Market Prospects & Outlook
- PCR Technology Leads the MDx Market
- Infectious Diseases: The Largest Application Market
- Reagents and Kits Dominate the Molecular Diagnostics Market
- Developing Countries Present Strong Growth Prospects
- Competition
- Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
- Rising Demand for Point of Care Diagnostics Augurs Well for Molecular POC Diagnostics Market
- Emphasis on Decentralized Diagnostics Presents Opportunity for POC Testing
- Growing Prevalence of Infectious Diseases Spurs Need for POC Molecular Diagnostics
- Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
- Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
- PCR Plays a Vital Role in the Diagnosis of Infectious Diseases
- Rising Prevalence of Respiratory Infections to Drive Need for POC Molecular Diagnostics
- Global Number of Deaths Caused Due to Communicable Diseases (In 000s)
- Rise in Pollution Levels Trigger Increase in Respiratory Diseases, Driving Market Opportunities
- Percentage Share Breakdown of Global Deaths Linked to Air Pollution
- Air Pollution Levels (PM2.5 Concentration (μg/m3) for Major Countries Worldwide for 2023
- Rising Cancer Incidence Drives Focus onto POC Molecular Diagnostics
- Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
- Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2022
- Number of New Cancer Cases and Deaths (in Million) by Region for 2023
- Rising Incidence of Hospital Acquired Infections (HAIs) Propels Demand for POC Molecular Diagnostics
- Sustained Threat of HIV and Sexually Transmitted Diseases Amplify Need for POC Molecular Diagnostics
- Global HIV Prevalence: Number of People Living with AIDs (in Thousands) by Region for 2022
- Number of AIDS-Related Deaths (in Thousands) by Region for 2022
- Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease
- Home HIV Testing Emerges as a Lucrative Option
- Molecular Tests Gaining Prominence in GC/Chlamydia Testing Market
- Molecular Diagnostics Opens New Avenues in Viral Hepatitis Testing
- Hepatitis B Prevalence Worldwide by Region
- Demand Continues to Surge for CLIA-Waived Molecular POC Tests
- Advancements in POC for Molecular Diagnostics to Drive Market Growth
- Nanotechnology Facilitates Development of for POC Molecular Diagnostics
- Healthcare Needs of the World's Aging Population: Potential Opportunity in Store
- Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
- Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
- Increase in Healthcare Spending in Emerging Markets to Propel Demand for POC Molecular Diagnostics
- World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
- Elderly Healthcare Expenditure as a % of GDP for 1970, 2010 and 2050
- Challenges Facing POC Molecular Diagnostics Market
4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 2: World Historic Review for PCR-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 3: World 16-Year Perspective for PCR-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 4: World Recent Past, Current & Future Analysis for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 5: World Historic Review for Genetic Sequencing-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 6: World 16-Year Perspective for Genetic Sequencing-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 7: World Recent Past, Current & Future Analysis for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 8: World Historic Review for Hybridization-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 9: World 16-Year Perspective for Hybridization-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 10: World Recent Past, Current & Future Analysis for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 11: World Historic Review for Microarray-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 12: World 16-Year Perspective for Microarray-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 16: World Recent Past, Current & Future Analysis for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 17: World Historic Review for Home Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 18: World 16-Year Perspective for Home Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 19: World Recent Past, Current & Future Analysis for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 20: World Historic Review for Assisted Living Healthcare Facilities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 21: World 16-Year Perspective for Assisted Living Healthcare Facilities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 22: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 23: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 24: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 25: World Recent Past, Current & Future Analysis for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 26: World Historic Review for Decentralized Labs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 27: World 16-Year Perspective for Decentralized Labs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 28: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 29: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 30: World 16-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 31: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 32: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 33: World 16-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 34: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 35: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 36: World 16-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 37: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 38: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 39: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
- TABLE 40: World Point of Care (POC) Molecular Diagnostics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
- TABLE 41: World Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 42: World Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 43: World 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

UNITED STATES
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
- TABLE 44: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 45: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 46: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 47: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 48: USA Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 49: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 50: USA Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 51: USA Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 52: USA 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
CANADA
- TABLE 53: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 54: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 55: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 56: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 57: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 58: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 59: Canada Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 60: Canada Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 61: Canada 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
JAPAN
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
- TABLE 62: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 63: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 64: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 65: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 66: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 67: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 68: Japan Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 69: Japan Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 70: Japan 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
CHINA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
- TABLE 71: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 72: China Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 73: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 74: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 75: China Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 76: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 77: China Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 78: China Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 79: China 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
EUROPE
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
- TABLE 80: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 81: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 82: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 83: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 84: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 85: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 86: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 87: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 88: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
- TABLE 89: Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 90: Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 91: Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
FRANCE
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
- TABLE 92: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 93: France Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 94: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 95: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 96: France Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 97: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 98: France Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 99: France Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 100: France 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
GERMANY
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
- TABLE 101: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 102: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 103: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 104: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 105: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 106: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 107: Germany Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 108: Germany Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 109: Germany 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
ITALY
- TABLE 110: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 111: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 112: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 113: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 114: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 115: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 116: Italy Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 117: Italy Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 118: Italy 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
UNITED KINGDOM
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
- TABLE 119: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 120: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 121: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 122: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 123: UK Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 124: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 125: UK Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 126: UK Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 127: UK 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
SPAIN
- TABLE 128: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 129: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 130: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 131: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 132: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 133: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 134: Spain Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 135: Spain Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 136: Spain 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
RUSSIA
- TABLE 137: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 138: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 139: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 140: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 141: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 142: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 143: Russia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 144: Russia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 145: Russia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
REST OF EUROPE
- TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 147: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 148: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 150: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 151: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 153: Rest of Europe Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 154: Rest of Europe 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
ASIA-PACIFIC
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
- TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 156: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 157: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 159: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 160: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 162: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 163: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
- TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 165: Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 166: Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
AUSTRALIA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
- TABLE 167: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 168: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 169: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 170: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 171: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 172: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 173: Australia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 174: Australia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 175: Australia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
INDIA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
- TABLE 176: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 177: India Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 178: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 179: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 180: India Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 181: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 182: India Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 183: India Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 184: India 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
SOUTH KOREA
- TABLE 185: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 186: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 187: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 188: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 189: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 190: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 191: South Korea Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 192: South Korea Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 193: South Korea 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
- TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 195: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 198: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 201: Rest of Asia-Pacific Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
LATIN AMERICA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
- TABLE 203: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 204: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 205: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 206: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 207: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 208: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 209: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 210: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 211: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
- TABLE 212: Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 213: Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 214: Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
ARGENTINA
- TABLE 215: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 216: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 217: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 218: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 219: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 220: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 221: Argentina Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 222: Argentina Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 223: Argentina 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
BRAZIL
- TABLE 224: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 225: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 226: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 227: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 228: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 229: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 230: Brazil Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 231: Brazil Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 232: Brazil 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
MEXICO
- TABLE 233: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 234: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 235: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 236: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 237: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 238: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 239: Mexico Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 240: Mexico Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 241: Mexico 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
- TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 243: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 244: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 246: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 247: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 249: Rest of Latin America Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 250: Rest of Latin America 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
MIDDLE EAST
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
- TABLE 251: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 252: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 253: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 254: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 255: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 256: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 257: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 258: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 259: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
- TABLE 260: Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
- TABLE 261: Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 262: Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
IRAN
- TABLE 263: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 264: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 265: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 266: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 267: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 268: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 269: Iran Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 270: Iran Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 271: Iran 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
ISRAEL
- TABLE 272: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 273: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 274: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 275: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 276: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 277: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 278: Israel Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 279: Israel Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 280: Israel 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
SAUDI ARABIA
- TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 282: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 283: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 285: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 286: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 288: Saudi Arabia Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 289: Saudi Arabia 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
- TABLE 290: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 291: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 292: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 293: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 294: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 295: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 296: UAE Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 297: UAE Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 298: UAE 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
- TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 300: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 301: Rest of Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 303: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 304: Rest of Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 306: Rest of Middle East Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 307: Rest of Middle East 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030
AFRICA
- Point of Care (POC) Molecular Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
- TABLE 308: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 309: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Technology - PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 310: Africa 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Technology - Percentage Breakdown of Value Sales for PCR-based, Genetic Sequencing-based, Hybridization-based and Microarray-based for the Years 2014, 2024 & 2030
- TABLE 311: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 312: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by End-Use - Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 313: Africa 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Home Care, Assisted Living Healthcare Facilities, Other End-Uses and Decentralized Labs for the Years 2014, 2024 & 2030
- TABLE 314: Africa Recent Past, Current & Future Analysis for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
- TABLE 315: Africa Historic Review for Point of Care (POC) Molecular Diagnostics by Application - Infectious Diseases, Oncology, Hematology and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
- TABLE 316: Africa 16-Year Perspective for Point of Care (POC) Molecular Diagnostics by Application - Percentage Breakdown of Value Sales for Infectious Diseases, Oncology, Hematology and Other Applications for the Years 2014, 2024 & 2030